The following funding news and opportunities were collected recently by Cancer Center Pre-Award Services and published in Cancer Center Update, a weekly e-newsletter for members and staff.

Visit the Research Funding Resources page for links to resources you can use to search for funding as well as University resources essential to application processes.

January 28

Ovarian Cancer Research Awards
Minnesota Ovarian Cancer Alliance (MOCA)
Deadline: March 7, 2008 (3 p.m.)
Funding: $100,000 ($25,000 for fellowships)
The Minnesota Ovarian Cancer Alliance will be awarding funds to provide opportunities for professionals to either initiate new studies or continue current research on ovarian cancer. All research proposals will be considered, however, special consideration will be given to proposals dealing with treatment.

Prostate Cancer Foundation Challenge Awards
Prostate Cancer Foundation (PCF)
Deadline: March 14, 2008
Funding: $300,000 - $1,000,000/yr for 3 years
This new award provides multi-year support for collaborative efforts in eight focus areas identified as potentially transformational to the field. PCF is seeking proposals from teams of at least three highly experienced investigators capable of providing unique scientific expertise to the solution of a significant problem in prostate cancer research. A team may be assembled from one institution, or from several institutions. PCF Challenge Awards are intended to accelerate progress towards the reduction of death and suffering due to recurrent or advanced prostate cancer and reward high risk-high return research ideas.

January 22

The Noa Schwartz Siris, M.D., Research Award (PDF)
Bone and Cancer Foundation
Deadline: February 15, 2008
Funding: $20,000

The Noa Schwartz Siris, M.D., Research Award will fund basic or clinical research on bone metastasis and osteosarcoma.

January 15

Innovative Technologies for Molecular Analysis of Cancer (R21)
(RFA-CA-08-006)
National Cancer Institute
Application Receipt Date(s): March 11, 2008; May 29, 2008; September 24, 2008
Funding: $500,000 (direct costs) for up to 3 years (no more than $200,000 in a year)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the inception and early stage development of highly innovative cancer-relevant technologies. The emphasis of this FOA is on technically innovative molecular analysis tools with the potential to add a new quality to the investigations of the molecular basis of cancer.

Application of Emerging Technologies for Cancer Research (R21)
(RFA-CA-08-007)
Application of Emerging Technologies for Cancer Research (R33)
(RFA-CA-08-008)
National Cancer Institute
Application Receipt Date(s): March 11, 2008; May 29, 2008; September 24, 2008
Funding: R21—2 years funding up to $275,000. R33—up to 3 years funding, amount depending on need

This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exploratory research projects focused on the application development for promising emerging cancer-relevant technologies. The emphasis of this FOA is on projects to evaluate the performance of emerging molecular analysis technologies and develop applications for an appropriate cancer-relevant biological system.

Innovative Technology Solutions to Cancer Sample Preparation (R21)
(RFA-CA-08-009)
Innovative Technology Solutions to Cancer Sample Preparation (R33)
(RFA-CA-08-010)
National Cancer Institute
Application Receipt Date(s): March 11, 2008; May 29, 2008; September 24, 2008
Funding: R21—2 years funding up to $275,000. R33—up to 3 years funding, amount depending on need

This Funding Opportunity Announcement (FOA) solicits developmental grant applications proposing research projects focused on the development and/or application of innovative technologies addressing various aspects of the preparation, purification, processing, and handling of cancer-relevant samples. The overall goal is to develop technologies that maximize the quality and utility of biospecimens for molecular analyses of cancer cells and their host environments without compromising donor/patient health.

Innovative and Applied Molecular Analysis Technologies for Cancer (SBIR [R43/R44])
(RFA-CA-08-011)
Innovative and Applied Molecular Analysis Technologies for Cancer (STTR [R41/R42])
(RFA-CA-08-012)
National Cancer Institute
Application Receipt Date(s): March 11, 2008; May 29, 2008; September 24, 2008
Funding: Phase I: 2 years, $100,000 total costs per year. Phase II: 3 years, $750,000 total costs per year

This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) proposing exploratory/developmental research projects focused on (i) the inception and early stage development of highly innovative cancer-relevant technologies and/or (ii) the evaluation of the performance of emerging molecular analysis technologies and development of applications for an appropriate cancer-relevant biological system. The emphasis of this FOA is on molecular analysis tools with the intent to develop cancer-relevant product-based technologies for the cancer research and clinical communities.

Innovative Technology Solutions to Cancer Sample Preparation (SBIR [R43/R44])
(RFA-CA-08-013)
Innovative Technology Solutions to Cancer Sample Preparation (STTR [R41/R42])
(RFA-CA-08-014)
National Cancer Institute
Application Receipt Date(s): March 11, 2008; May 29, 2008; September 24, 2008
Funding: Phase I: 2 years, $100,000 total costs per year. Phase II: 3 years, $750,000 total costs per year

This Funding Opportunity Announcement (FOA) solicits grant applications from small business concerns (SBCs) proposing research projects focused on the development and/or application of innovative technologies addressing various aspects of the preparation, purification, processing, and handling of cancer-relevant samples. The overall goal is to develop technologies that maximize the quality and utility of biospecimens for molecular analyses of cancer cells and their host environments without compromising donor/patient health.

January 8

2008 Advanced Clinical Research Award in Breast Cancer
The ASCO Foundation
Deadline: Letter of Intent due January 15, 2008, Application due: February 14. 2008
Award term: July 1, 2008- June 30, 2011
Funding: $450,000 in 3 annual increments of $150,000.

The Advanced Clinical Research Award is designed to provide funding to investigators who are committed to clinical cancer research, and is intended to support original research not currently funded. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. By continuing to support proven clinical researchers at a critical stage in their early career, ASCO hopes to expand the cadre of expert clinical oncology researchers who are developing promising research initiatives.

Applicants must be physicians (M.D., D.O., or international equivalent), 5-10 years post final subspecialty training, with full time faculty appointments in a clinical department at an academic health center. Applicants must be active members of ASCO and are expected to spend 75% of their time during the award period dedication to research.

Translational Research Program 2008
Leukemia & Lymphoma Society
Deadlines: Letter of Intent due March 1, 2008, 3 p.m. EST. Full application due March 15, 2008, 3 p.m. EST.
Funding: $200,000, which includes direct costs and a maximum overhead of $20,000 or 11.1 percent of direct costs per year for three years.

The Leukemia & Lymphoma Society's Translational Research Program was established to encourage and provide support for new and novel clinical research. The goal of the program is to accelerate transfer of findings from the laboratory to clinical application. The program's purpose is to fund research that shows high promise for translating basic biomedical knowledge to prevention or new treatments and, ultimately, to prolong and enhance life.

The grant may be funded for an additional two years if it includes an approved clinical trial and a fully justified research plan. A principal intent of the program is to permit the acquisition of sufficient data to apply to an appropriate agency or sponsor for sustained support.

January 1

Cancer Center Update was not published because of holiday.